Abstract
The Alzheimer amyloid precursor protein (APP) is a transmembrane protein whose abnormal processing is associated with the pathogenesis of Alzheimer's disease. Activated caspases cleave APP and generate its carboxyl-terminally truncated fragment (APPΔC31). We have previously reported that overexpression of wild-type APP induces caspase-3 activation and apoptosis in postmitotic neurons. We now report that APPΔC31 potentially plays pathophysiological roles in neuronal death. Adenovirus-mediated overexpression of wild-type APP695 induced activation of caspase-3 and accumulation of APPΔC31 in postmitotic neurons derived from human NT2 embryonal carcinoma cells, whereas an APP mutant lacking the Aβ(1–20) region induced neither caspase-3 activation nor APPΔC31 generation. Inhibition of caspase-3 suppressed the generation of APPΔC31 in APP-overexpressing neurons. Forced expression of APPΔC31 induced apoptotic changes of neurons and non-neuronal cells, but failed to activate caspase-3. The cytotoxicity of APPΔC31 was also dependent on the Aβ(1–20) region. These results suggest that accumulation of wild-type APP activates neuronal caspase-3 to generate APPΔC31 that mediates caspase-3-independent cell death.
Similar content being viewed by others
Introduction
Alzheimer's disease (AD) is a neurodegenerative disease characterized by massive amounts of neuronal death associated with histopathological hallmarks such as extracellular deposition of amyloid fibrils and intracellular accumulation of neurofibrillary tangles. The principal constituent of the amyloid fibrils is β/A4 (Aβ)1 which is generated by processing of the amyloid precursor protein (APP). APP and Aβ have been considered as key molecules involved in the pathogenesis of AD.2,3,4,5 APP695, an APP isoform lacking the protease inhibitor domain, is abundantly expressed in postmitotic neurons during early periods of their differentiation.6 However, physiological and pathological roles of APP in neurons remain largely unknown. Earlier studies using APP-deficient cells suggest that cell-associated APP enhances neuronal survival and exerts neuroprotective functions.7,8 In contrast, we have previously reported that overexpression of wild-type APP695 induced death of postmitotic neurons derived from murine embryonal carcinoma P19 cells.6 Furthermore, viral vector-mediated overexpression of wild-type APP induces apoptosis-like death of postmitotic neurons both in vivo and in vitro.9,10,11,12 In APP-accumulating neurons in vitro, caspase-3 is activated in a cleavage-dependent manner, and a caspase-3 inhibitor significantly reduces the severity of degeneration exhibited by APP-overexpressing neurons.11 These observations suggest that unphysiological levels of wild-type APP induce neuronal apoptosis in a caspase-dependent manner.
Caspases have a regulatory role in programmed death of chick spinal motoneurons,13 in which APP expression is upregulated during the course of cell death.14 Neurodegenerative insults induce cytoplasmic cleavage of endogenous APP by caspases and generate an APP fragment that lacks the carboxyl (C)-terminal 31-residue region (APPΔC31).15 Caspase-6, which is activated in apoptotic neurons under serum-deprived conditions, cleaves APP directly at the cytoplasmic domain and generates Aβ-containing fragments.16 These findings suggest a close link between APP and the caspase-mediated death machinery.
In this study, we demonstrate that APPΔC31 per se exerts cytotoxic effects on human postmitotic neurons and its precursor stem cells. Immunocytochemistry using end-specific antibodies against caspase-cleaved APP fragments revealed that wild-type APP undergoes proteolytic processing into APPΔC31 and APP665–695 (APP-C31) when overexpressed in postmitotic neurons. We also show that APPΔC31 induces nuclear changes indicative of apoptosis in postmitotic neurons and non-neuronal cells but fails to activate caspase-3. These findings raise the possibility that this caspase-cleaved form of APP has its own role in the modulation of neuronal death.
Results
Activation of caspase-3 and generation of APPΔC31 in neurons by serum deprivation
We raised end-specific antibodies against activated caspase-3 subunits (ACP3) and the C-terminus of APPΔC31 (SAC) to detect intraneuronal caspase-3 activation and APPΔC31 generation. It has been reported that neurodegenerative insults activate neuronal caspases that cleave endogenous APP into APPΔC31.15 We used postmitotic neurons under serum-deprived conditions to test the specificities and sensitivities of these antibodies (Figure 1). Differentiated neurons, which were identified by staining for the neuronal marker microtubule-associated protein 2 (MAP2), showed apoptotic features such as nuclear fragmentation and condensation by serum deprivation for 96 h. Immunocytochemistry using these antibodies revealed that these apoptotic neurons contained both activated caspase-3 and APPΔC31. In contrast, MAP2-positive neurons had neither activated caspase-3 nor APPΔC31 under serum-supplemented conditions. These data suggest that neuronal caspases are activated by serum-deprivation and cleave endogenous APP at the cytoplasmic domain, and that the end-specific antibodies ACP3 and SAC properly recognize activated caspase-3 subunits and the C-terminus of APPΔC31, respectively.
Neuronal caspase-3-activation by accumulation of wild-type APP is dependent on the Aβ domain
We infected recombinant adenoviruses expressing wild-type APP and its mutant lacking the Aβ(1–20) region (APPΔAβ20) into neurally differentiated NT2 neurons (Figure 2A). APP-accumulating neurons had condensed, fragmented nuclei and active caspase-3 subunits 48 h after infection, whereas a few neurons overexpressing APPΔAβ20 or β-galactosidase (β-Gal) were positively stained for activated caspase-3. Quantification of caspase-3-immunopositive neurons revealed that 40% of neurons accumulating wild-type APP contained activated caspase-3 at 48 h (Figure 2B). Under these conditions, the population of caspase-3-immunopositive neurons among APPΔAβ20-accumulating neurons was similar to that of β-Gal-accumulating neurons (∼10%). When dead neurons were quantified using ethidium homodimer-1 (EthD-1), a fluorescent dye excluded by viable cells, 36% of neurons accumulating wild-type APP were found to be dead at 72 h (Figure 2C). In contrast, the population of dead neurons among APPΔAβ20-accumulating neurons was ∼6%, a level similar to that of β-Gal-accumulating neurons. These results suggest that the Aβ(1–20) region of APP is required for activation of neuronal caspase-3.
Cleavage of APP at the cytoplasmic site in neurons overexpressing wild-type APP
Because the cytoplasmic region of wild-type APP695 contains the caspase cleavage site (VEVD), overexpressed full-length APP can be cleaved by caspases into the 664-residue amino (N)-terminal fragment (APPΔC31) and the 31-residue C-terminal fragment (APP-C31). Using antibodies against the C-terminal end of APPΔC31 (SAC) and the N-terminal end of APP-C31 (ACT1), we examined whether APPΔC31 and APP-C31 are actually generated in postmitotic neurons overexpressing wild-type APP. APP-overexpressing NT2 neurons were stained for the N-terminus of APP with antibody P2-1 and chromosomal DNA with Hoechst 33342 (Figure 3A). Most of wild-type APP-accumulating neurons had shrunken and fragmented nuclei. These apoptotic neurons were immunopositive for both APPΔC31 and APP-C31 at 72 h as judged by staining with SAC and ACT1, respectively. In contrast, APPΔC31 and APP-C31 were hardly detected in APPΔAβ20-accumulating neurons or APP-accumulating non-neuronal cells in the mixed cultures.
To examine whether caspase-3 is involved in the cleavage of APP at the cytoplasmic site, we treated APP-overexpressing neurons with the cell permeable caspase-3 inhibitor carbobenzoxy-Asp-Glu-Val-Asp-fluoromethylketone (Z-DEVD-FMK) and examined the generation of APPΔC31 and APP-C31 with the end-specific antibodies SAC and ACT1 (Figure 3B). In the absence of the inhibitor, 44% and 29% of APP-accumulating neurons were found to be immunopositive for SAC and ACT1 immunoreactivities, respectively. In the presence of the inhibitor (150 μM), the proportions of APPΔC31- and APP-C31-accumulating neurons were significantly decreased to 18% and 13%, respectively. The inhibitor had no appreciable effects on the proportions of SAC- and ACT1-immunopositive neurons that overexpressed APPΔAβ20. These results suggest that activated caspase-3 caused by intracellular accumulation of wild-type APP substantially cleaves APP at the cytoplasmic site.
Western blot analysis revealed that wild-type APP and mutant proteins were abundantly expressed as analyzed using antibodies against the C-terminus of APP (AC1) (Figure 4A) and the N-terminus (AN2) (Figure 4B, upper panel). Neurons overexpressing wild-type APP contained a 96 kDa SAC-immunoreactive fragment, which was detected in APPΔC31-overexpressing neurons (Figure 4B, lower panel). The amount of APPΔC31 in neurons overexpressing wild-type APP was similar to that in neurons overexpressing APPΔC31, suggesting that a considerable amount of wild-type APP is processed into APPΔC31. In contrast, APPΔC31 was undetected in neurons overexpressing APPΔAβ20 or β-Gal. These results, together with the data shown in Figures 2 and 3, suggest that overexpression of wild-type APP activates neuronal caspases that eventually cleave APP at the cytoplasmic site.
We have previously shown that a C-terminal 100 amino acid fragment of APP (APP-C100), which encompasses the Aβ domain and the C31 region, forms amyloid fibril-like structures in cDNA-transfected COS cells.17 We then examined whether full-length APP self-associates when accumulated on the membrane. Cell surface proteins in NT2 neurons infected with recombinant adenoviruses expressing β-Gal, wild-type APP, APPΔAβ20 and APPΔC31 were treated with a membrane-impermeable cross-linker and analyzed by Western blotting using the antibody against the N-terminus of APP (AN2) (Figure 4C). APP immunoreactive bands were detected at ∼110 kDa and >220 kDa. The >220 kDa bands, which may correspond to APP cross-linked with other membrane proteins, were undetected in the absence of the cross-linker (data not shown). Only the neurons overexpressing wild-type APP contained a distinct ∼220 kDa APP immunoreactive band, whose size corresponds to that of the APP homodimer. These results suggest that the transmembrane form of APP tend to self-associate when concentrated on the membrane.
Caspase-3-independent neuronal death induced by APPΔC31
Because APPΔC31 was generated in neurons overexpressing wild-type APP, we then examined whether APPΔC31 per se affects neuronal viability. We constructed the adenovirus vector expressing APPΔC31 (AxCAPΔC31) and infected it into NT2 neurons (Figure 5). A number of APPΔC31-expressing neurons underwent death as analyzed by EthD-1 retention test (top panels). These degenerated neurons had nuclei stained positively by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) (middle panels). Intriguingly, APPΔC31-accumulating neurons carrying apoptotic nuclei contained little or no activated caspase-3-immunoreactivity (bottom panels). These results suggest that APPΔC31 induces neuronal apoptosis in a caspase-3-independent manner.
Quantification of neuron death by the EthD-1 retention assay revealed that 28% of APPΔC31-expressing neurons were dead. Under the same conditions, β-Gal and wild-type APP caused neuron death at 7% and 33%, respectively (Figure 6A). We then measured caspase-3-like protease activity in neurons overexpressing wild-type APP, APPΔC31, APPΔAβ20, or β-Gal using the fluorogenic substrate carbobenzoxy-Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin (Z-DEVD-AFC) (Figure 6B). In agreement with the immunocytochemical data shown in Figures 2A and 5, caspase-3-like activities in APPΔC31, APPΔAβ20, and β-Gal-overexpressing neurons remained low during the 96-h incubation period, whereas the activity in wild-type APP-overexpressing neurons increased and reached a peak at 48 h.
Cytotoxicity of APPΔC31 is not specific to postmitotic neurons
We have previously shown that caspase-3-mediated apoptosis by wild-type APP is specific to postmitotic neurons.11 The present study has shown that APPΔC31 induced caspase-3-independent neuronal death. These findings suggested that APPΔC31 induces apoptosis in a manner distinct from that of wild-type APP. When NT2 embryonal carcinoma stem cells (NT2S) and differentiated neurons (NT2N) were infected with the adenovirus vector expressing APPΔC31, some of the stem cells and neurons showed apoptotic changes and EthD-1 retention (Figure 7). In contrast, most of the stem cells overexpressing wild-type APP were morphologically intact and showed little or no EthD-1 retention.
We then quantified the cytotoxic effects of β-Gal, APPΔC31, wild-type APP, and APPΔAβ20 on NT2 stem cells and transformed cell lines (Figure 8A). Only APPΔC31 caused a significant increase in the dead population of non-neuronal cells such as NT2 stem cells, African green monkey kidney COS-1 cells, human glioma Bu17 cells, and human cervical carcinoma HeLa cells. The cytotoxic effects of wild-type APP and APPΔAβ20 were hardly detected in these non-neuronal cells as compared with the values of the negative control of β-Gal (P>0.05). In contrast, the cytotoxic effect of wild-type APP was seen only in NT2 neurons. These results indicate that APPΔC31, unlike wild-type APP, is cytotoxic to non-neuronal cells as well as to postmitotic neurons.
In order to examine whether the Aβ(1–20) domain in APPΔC31 is responsible for its cytotoxicity, we constructed a vector expressing an APP mutant lacking both the Aβ(1–20) and C-terminal 31-residue regions (termed APPΔAβ20/C31) and transfected it into COS-1 cells. The EthD-1 retention assay revealed that 32% of APPΔC31-expressing cells were dead (Figure 8B). In this assay system, the cytotoxic level of APPΔAβ20/C31 was similar to those (∼15% dead cells) of wild-type APP, β-Gal and APPΔAβ20, which showed only the non-specific viral cytotoxicity. These findings suggest that the Aβ(1–20) region of APPΔC31 is indispensable for its cytotoxity.
Discussion
Caspase-3-independent apoptosis induced by APPΔC31
Recent studies have demonstrated that APP is cleaved by caspases at Asp 664.14,15,16,18,19,20 The present immunocytochemical study has shown that apoptotic neurons under serum-deprived conditions contained activated caspase-3 subunits and APPΔC31 (Figure 1). Furthermore, both APPΔC31 and APP-C31 were detected in neurons overexpressing wild-type APP (Figure 3A). Generation of these fragments were significantly suppressed by treatment with caspase-3 inhibitor (Figure 3B). These findings suggest that overexpression of wild-type APP causes activation of caspases that subsequently cleave APP at the cytoplasmic Asp664 site (Figures 2A,B and 6B). Intriguingly, APPΔC31 per se caused apoptosis of neurons in a caspase-3-independent manner (Figures 5 and 6). We also found that overexpression of APPΔC31 caused death of non-neuronal cells including proliferative neural precursor cells and transformed cell lines originating from non-neuronal tissues (Figures 7 and 8A), indicating that the cytotoxic effects of APPΔC31 are independent of cell species and their differentiation states. APP-C31, which is the counterpart of APPΔC31 generated by caspase cleavage, has recently been reported to act as a cytotoxic peptide in cells treated with apoptosis-inducing agents.20 Thus, it is inferred that proteolytic processing of APP by caspases concomitantly generates APPΔC31 and APP-C31 that exert their effects on cell death.
The molecular mechanisms whereby APPΔC31 causes apoptotic cell death remain to be elucidated. Activated caspase-3 was undetected in neurons overexpressing APPΔC31 (Figures 5 and 6B). Furthermore, we were unable to detect the activation of other caspases such as caspases-7, -6, -8, and -9 or upregulation of the endoplasmic reticulum stress marker proteins such as Grp78 and GADD153 (I Nishimura and K Yoshikawa, unpublished observations). The APPΔC31-induced cytotoxicity has previously been assessed using mouse neuroblastoma cells treated with the apoptosis-inducing compounds staurosporine and tamoxifen.20 APPΔC31 had no cytotoxic effects on the neuroblastoma cells treated with staurosporine. However, they also reported that APPΔC31 significantly reduced the cell viability when treated with tamoxifen. We have found that rodent cells require higher titers of APP-expressing adenoviruses than primate cells to undergo similar changes. We thus used primate cell lines infected with lower titers of adenovirus to demonstrate the cytotoxic effects of APP and APPΔC31 in the present study. Thus we infer that cytotoxicity of APPΔC31 is dependent on various factors such as cell types, APPΔC31 expression levels, and presence of other cytotoxic agents.
In APP-overexpressing neurons, APP and subsequently generated APPΔC31 would show additive or cooperative toxicity because they both have cytotoxic effects. However, we found that the neurotoxic potency of wild-type APP was similar to that of APPΔC31 (Figure 6A). We used adenovirus titers that show a dead population of ∼30% among total infected cells, because higher titers exert non-specific toxicity as generally observed in the adenovirus gene transfer system. Under these conditions, each infected neuron responds to APP with either death or survival. Thus, the fate of each APP-accumulating neuron cannot be changed even when cytotoxic APPΔC31 is generated within the same cell. We speculate that this is the reason why wild-type APP (plus endogenously generated APPΔC31) and APPΔC31 showed similar cytotoxic potencies.
Some intracellular proteins have been reported to gain pathophysiological functions when cleaved by caspases. For example, Acinus and transcription factor NRF2 are cleaved by caspases and their cleaved products function as effectors for apoptosis.21,22 Furthermore, tau, a microtubule-associated protein whose abnormal phosphorylation is thought to cause formation of neurofibrillary tangles seen in AD, is cleaved by caspase-3 in vitro, and overexpression of the caspase-cleaved N-terminal fragment of tau induces apoptosis of NT2 stem cells and COS cells.23,24 These findings, together with our present findings, raise the possibility that caspase-cleaved products of endogenous APP and tau, whose posttranslational modifications are believed to be involved in the pathogenesis of AD, directly induce neuronal death.
Neuronal specificity of caspase-mediated apoptosis induced by wild-type APP
Overexpression of wild-type APP causes caspase-3-mediated apoptosis of postmitotic neurons but not of non-neuronal cells,11 suggesting that a neuron-specific machinery is involved in APP-induced caspase-3 activation. It has been demonstrated that two adaptor proteins, mammalian Disabled and FE65, which are primarily expressed in neurons, interact with the cytoplasmic tail of APP that contains the adaptor protein-binding motif NPTY.25 This suggests that APP acts as a neuronal surface receptor that mediates intracellular signal transduction. Thus, APP-binding adaptor proteins such as Disabled and FE65 may contribute to the neuronal specificity of APP-induced caspase-3 activation. This idea is supported by the present findings that APPΔC31, which lacks the adaptor-binding C31 region, failed to activate caspase-3 (Figures 5 and 6B). Another possibility is that neuron-specific ion channels or neurotransmitter receptors are involved in APP-induced neuronal apoptosis. We have previously reported that wild-type APP increases glutamate-induced Ca2+ influx into neuronal cytoplasm.26 Furthermore, we have recently found that APP causes elevation of intracellular Ca2+ levels in postmitotic neurons prior to caspase-3 activation (manuscript in preparation). These findings suggest that Ca2+ channels or molecules regulating Ca2+ channel activities are involved in caspase-3 activation caused by wild-type APP.
Transgenic mice carrying APP mutants such as APP (Val717Phe)27 and APP695 (Lys670Asn/Met671Leu)28 have been reported to show neuropathological changes accompanied by extracellular Aβ depositions. However, no overt neuronal loss is detected in the brain regions in which Aβ is extensively deposited in APP (Val717Phe) transgenic mice,29 suggesting that extracellular Aβ deposits per se are not toxic to neurons. The APP mutants in the transgenic mice in vivo may not be accumulated to toxic levels within neurons, whereas adenovirus-mediated overexpression of wild-type APP in vivo and in vitro induces a rapid elevation of APP levels sufficient for neuronal caspase-3 activation.10,11
Self-association of APP may be responsible for caspase-3 activation
It is noteworthy that the APP mutant lacking the Aβ(1–20) domain (APPΔAβ20), like APPΔC31, induced no neuronal caspase-3 activation (Figures 2A,B and 6B). These findings suggest that both the Aβ domain and the cytoplasmic C31 region are indispensable for caspase-3 activation. We have previously reported that a C-terminal 100 amino acid fragment of APP, termed APP-C100, forms amyloid fibril-like structures in cDNA-transfected COS cells.17 APP-C100 which encompasses the Aβ and cytoplasmic C31 regions, is neurotoxic in vitro and in vivo.5 Thus, we speculate the self-associating nature of the C-terminal region of APP is responsible for the caspase-3 activation and neuronal death. The cross-linking experiment revealed that wild-type APP-overexpressing neurons contained the ∼220 kDa APP-immunoreactive band (Figure 4C), suggesting that wild-type APP, which comprises intact APP-C100 region, is prone to self-associate to form homodimer when accumulated on the membrane. It has recently been reported that antibodies against subsequences of the extracellular APP domain induce neuronal apoptosis.30,31 A monoclonal antibody (22C11) against the extracellular APP66–81 region induces caspase-3 activation and apoptosis in neurons, suggesting that the antibody facilitates APP dimerization and activates the caspase pathway.30 Furthermore, we confirmed that antibody 22C11 induced caspase-3 activation and apoptosis in NT2 neurons within 24 h (I Nishimura and K Yoshikawa, unpublished observations). These findings together suggest that self-association of APP on the cell surface triggers the caspase cascade in neuronal cytoplasm.
Pathophysiological implications of APP-induced neuronal death
Based on the present findings, we schematized our hypothesis for APP-induced events operative in postmitotic neurons (Figure 9). Earlier studies have revealed that pathological stimuli and trophic factor deprivation upregulate endogenous APP levels.14,32,33 Furthermore, histopathological studies have revealed that neurons in AD brain contain abnormally dense APP-immunoreactive materials.34,35,36 Thus, neurons may have a propensity to accumulate APP in response to various insults ranging from trophic factor deprivation to neurotoxic stimuli. This phenomenon can be a compensatory response of stressed neurons to protect themselves against degeneration because cell-associated APP possesses neuroprotective functions.7,8 When the amounts of APP accumulations in affected neurons reach abnormally high levels, APP may in turn start to self-associate and activate caspases. Neuron-specific machinery including intracellular signal transduction molecules, ion channels, or neurotransmitter receptors may be involved in caspase activation. The caspase-cleaved transmembrane fragment APPΔC31 may facilitate neuronal death in cooperation with other caspase-cleavable death effectors. The present findings that APPΔAβ20 and APPΔAβ20/C31, both of which lack the Aβ(1–20) region, failed to induce appreciable cell death lead to the speculation that the Aβ(1–20) region is indispensable for apoptosis by both caspase-dependent and -independent pathways. It might be of particular interest to examine whether such events are actually operative in neurons that are eliminated during nervous system development and under neurodegenerative conditions such as AD.
Materials and Methods
Recombinant adenoviruses
Recombinant adenoviruses expressing wild-type APP and its mutants were constructed as previously.10,11 Sequences encoding APP mutants were synthesized by polymerase chain reaction (PCR)-mediated template modification. PCR was performed using primers carrying mutated sequences and restriction site (BglII, SalI) at the ends and human full-length APP695 cDNA as a template.6,37 To construct cDNA of Aβ(1–20)-lacking APP (APPΔAβ20), a PCR product lacking Aβ(1–20) region was inserted between BglII and SalI sites of APP695 cDNA. To construct APPΔC31, a sequence corresponding APP (amino acids 576–664) was amplified by PCR with a primer that carries two stop codons at the 3′ end and inserted in APP cDNA. APPΔAβ20 and APPΔcC31 DNAs were fully sequenced, blunt-ended, and subcloned at the SwaI site of pAxCAwt. Cosmid DNA was cotransfected with the EcoT221-digested DNA-terminal protein complex of Ad5-dlX into 293 cells to generate recombinant viruses by homologous recombination. Adenovirus vectors expressing wild-type APP, APPΔAβ20, and APPΔC31 were designated as AxCAYAP, AxCAPΔAβ20, and AxCAPΔC31, respectively. Adenovirus expressing β-galactosidase (β-Gal) (AxCALacZ) was provided by Dr. I Saito (University of Tokyo, Tokyo, Japan). Propagation, and titration of recombinant adenoviruses were performed as described previously.10,11 Experiments using recombinant adenoviruses were approved by the Recombinant DNA Committee of the Osaka University and performed according to the institutional guidelines.
Adenovirus infection into cultured cells
Human embryonal carcinoma cells of NTera2/cl.D1 (NT2) cell line38 (Stratagene, La Jolla, CA, USA) were cultured and neurally differentiated as reported previously.11,39 Briefly, NT2 cells were treated with 10 μM all-trans retinoic acid (Sigma, St. Louis, MO, USA) for 30 days and subcultured at ∼3.0×105 cells per 35 mm dish at 37°C and 5% CO2 in the medium Opti-MEM (Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS) containing 1 μM cytosine arabinoside (Sigma) to obtain enriched postmitotic neurons. Serum-deprived neuronal cultures were obtained by incubating neurons in the absence of FCS for 96 h. COS-1 cells, human Bu17 glioma cells, and HeLa cells were cultured in the medium Dulbecco's modified Eagle medium supplemented with 10% FCS. NT2 neurons and other cells were exposed to recombinant adenovirus vectors at 2×107 pfu/ml culture medium for 12 h (multiplicity of infection 25–50) and then incubated in a virus-free fresh medium up to 96 h.11
Antibodies
End-specific antibodies against activated caspase-3 p20/p17 subunits (ACP3), APPΔC31 (SAC), and APP-C31 (ACT1) were raised in rabbits against synthetic peptides corresponding to the caspase-3 cleavage site,40 APP 658–664 of APP695,15 APP 665–670 of APP695, respectively. Immunoglobulins G (IgGs) of SAC and ACT1 were depleted of IgG recognizing a bridging peptide corresponding to APP (amino acids 657–670) that spans the caspase cleavage site by affinity chromatography (ProtOn Kit1, Multiple Peptide Systems, San Diego, CA, USA). End-specific reactivities of the antibodies ACP3, SAC, and ACT1 were confirmed by ELISA titration, Western blotting analysis, and immunocytochemistry. Other antibodies used are: a mouse monoclonal antibody against MAP2 (Chemicon, Temecula, CA, USA); a rabbit polyclonal antibody against β-Gal (Cappel, Aurora, OH, USA); a mouse monoclonal antibody P2-1 against the N-terminus of APP41 (a gift from Dr. Van Nostrand); a rabbit polyclonal antibody against APP (amino acids 671–695) (AC1);6 a rabbit polyclonal antibody against APP (amino acids 18–38) (AN2).
Immunocytochemistry
NT2 neurons and other cells grown on coverslips were fixed 48–72 h after adenovirus infections with 4% formaldehyde in phosphate-buffered saline (PBS) (pH 7.4) at 4°C for 20 min and permeabilized with acetone at −20°C for 20 min. Then, fixed cells were incubated with primary antibodies in PBS containing 0.05% Tween 20 at 4°C overnight. The cells were then incubated at room temperature for 1 h with anti-rabbit and anti-mouse IgGs conjugated with fluorescein isothiocyanate (FITC) or rhodamine (Cappel). For chromosomal DNA staining, cells were incubated with 5 μM Hoechst 33342 (Sigma) in PBS at room temperature for 10 min. Nuclear DNA fragmentation was analyzed by the TUNEL method.42 combined with immunostaining for APP with P2-1. TUNEL reactivity and APP were visualized with Texas Red and FITC, respectively. For caspase-3 inhibitor protection analysis, NT2 neurons were preincubated for 1 h with DMSO vehicle or Z-DEVD-FMK (Caspase-3 Inhibitor II; Calbiochem, La Jolla, CA, USA), infected with adenoviruses, and cultured for 72 h. After fixation, NT2 neurons were immunostained for APPΔC31 with SAC and for APP-C31 with ACT1. Immunoreactive images were observed by fluorescence microscopy (BX50-34-FLAD1, Olympus, Tokyo, Japan).
Cell death analysis
NT2 neurons and other cells were infected with adenoviruses, and 48 h or 72 h later the cells were incubated with 10 μM EthD-1 (Molecular Probes, Eugene, OR, USA) in PBS at 37°C for 30 min. After fixation, the cells were incubated with the antibody P2-1 against the N-terminus of APP and anti-β-Gal antibody, and subsequently incubated with FITC-conjugated anti-mouse and anti-rabbit IgGs, respectively. EthD-1-positive cells among 100–200 APP- and β-Gal-positive cells were counted by choosing five random fields per each dish and expressed as a percentage. Statistical significance was tested using Student's t-test.
Cross-linking of cell surface proteins
NT2 neurons were infected with adenoviruses. The cells were washed 24 h later with a buffer containing 137 mM NaCl, 5.3 mM KCl, 170 μM Na2HPO4, 220 μM KH2PO4, 10 mM HEPES, (pH 7.3), 33 mM glucose, and 44 mM sucrose and incubated with 1 mg/ml bis (sulfosuccinimidyl) suberate (Pierce, Rockford, IL, USA) in the buffer for 30 min at 37°C. After cross-linking, neurons were harvested, and their lysates were analyzed by Western blot analysis.
Western blot analysis
NT2 neurons infected with adenovirus were dislodged by pipetting the medium up and down with a Pasteur pipette several times. Most of the non-neuronal cells remained attached after this treatment. Detached neurons were then collected by centrifugation at 120×g for 5 min. Enriched neurons were resuspended in the buffer containing 10 mM Tris-HCl, pH 7.4, 100 μM phenylmethanesulfonyl fluoride, 10 μM pepstatin, 10 μM leupeptin, and 2 μg/ml aprotinin. The homogenates were centrifuged at 15 000×g for 30 min, and proteins (2 μg per lane) in the pellets (membrane fraction) were separated by 7.5% SDS-polyacrylamide gel electrophoresis. For analysis of cross-linked cell extracts, 2 μg proteins were separated by 6% SDS-polyacrylamide gel electrophoresis. Proteins were transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA), and blotted with AC1, AN2, and SAC. The membrane was incubated with peroxidase-labeled anti-rabbit IgG, and the signals were detected with chemiluminescence reagents (Renaissance Plus; NEN, Boston, MA, USA).
Measurement of caspase-3-like protease activity
Adenovirus-infected NT2 neurons were collected and incubated on ice for 10 min in a cell lysis buffer for caspase activity assay (MBL, Nagoya, Japan). Lysates were centrifuged at 15 000×g for 10 min at 4°C, and the supernatant (10 μg protein) was used for caspase-3-like protease assay. Caspase-3-like activity was measured by cleavage of the fluorogenic substrate Z-DEVD-AFC using a kit (FluorAce Apopain kit; Bio-Rad, Hercules, CA, USA) and a spectrofluorometer (VersaFluor; Bio-Rad). One unit was defined as the amount of enzyme required to cleave 1 pmol AFC per 60 min incubation at 37°C.
COS-1 cytotoxic assay
cDNA encoding an APP mutant lacking both the Aβ(1–20) and the C-terminal 31-residue regions (APPΔAβ20/C31) was constructed by PCR using primers for APPΔC31 and APPΔAβ20 cDNAs as described above. β-Gal, wild-type APP, APPΔAβ20, APPΔC31, and APPΔAβ20/C31 cDNAs were subcloned into pcDNA3.1(+) carrying the cytomegalovirus promoter (Invitrogen, San Diego, CA, USA). Vectors expressing APPs and β-Gal (1 μg per assay) were introduced into COS-1 cells using Lipofectamine Plus (Gibco, Gaithersburg, MD, USA), and cell death was analyzed at 72 h as above.
Abbreviations
- APP:
-
amyloid precursor protein
- AD:
-
Alzheimer's disease
- Aβ:
-
β/A4
- MAP2:
-
microtubule-associated protein 2
- β-Gal:
-
β-galactosidase
- EthD-1:
-
ethidium homodimer-1
- TUNEL:
-
terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling
- Z-DEVD-FMK:
-
carbobenzoxy-Asp-Glu-Val-Asp-fluoromethylketone
- Z-DEVD-AFC:
-
carbobenzoxy-Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin
- PCR:
-
polymerase chain reaction
- FCS:
-
fetal calf serum
References
Glenner GG, Wong CW . 1984 Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem. Biophys. Res. Commun. 120: 885–890
Selkoe DJ . 1994 Normal and abnormal biology of the β-amyloid precursor protein Annu. Rev. Neurosci. 17: 489–517
Yankner BA . 1996 Mechanisms of neuronal degeneration in Alzheimer's disease Neuron 16: 921–932
Mattson MP . 1997 Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives Physiol. Rev. 77: 1081–1132
Neve RL, McPhie DL, Chen Y . 2000 Alzheimer's disease: a dysfunction of the amyloid precursor protein Brain Res. 886: 54–66
Yoshikawa K, Aizawa T, Hayashi Y . 1992 Degeneration in vitro of post-mitotic neurons overexpressing the Alzheimer amyloid protein precursor Nature 359: 64–67
Perez RG, Zheng H, Van der Ploeg LH, Koo EH . 1997 The β-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity J. Neurosci. 17: 9407–9414
Xu X, Yang D, Wyss-Coray T, Yan J, Gan L, Sun Y, Mucke L . 1999 Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis Proc. Natl. Acad. Sci. USA 96: 7547–7552
Bursztajn S, DeSouza R, McPhie DL, Berman SA, Shioi J, Robakis NK, Neve RL . 1998 Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis J. Neurosci. 18: 9790–9799
Nishimura I, Uetsuki T, Dani SU, Ohsawa Y, Saito I, Okamura H, Uchiyama Y, Yoshikawa K . 1998 Degeneration in vivo of rat hippocampal neurons by wild-type Alzheimer amyloid precursor protein overexpressed by adenovirus-mediated gene transfer J. Neurosci. 18: 2387–2398
Uetsuki T, Takemoto K, Nishimura I, Okamoto M, Niinobe M, Momoi T, Miura M, Yoshikawa K . 1999 Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein J. Neurosci. 19: 6955–6964
Masumura M, Hata R, Nishimura I, Uetsuki T, Sawada T, Yoshikawa K . 2000 Caspase-3 activation and inflammatory responses in rat hippocampus inoculated with a recombinant adenovirus expressing the Alzheimer amyloid precursor protein Brain Res. Mol. Brain Res. 80: 219–227
Milligan CE, Prevette D, Yaginuma H, Homma S, Cardwell C, Fritz LC, Tomaselli KJ, Oppenheim RW, Schwartz LM . 1995 Peptide inhibitors of the ICE protease family arrest programmed cell death of motoneurons in vivo and in vitro Neuron 15: 385–393
Barnes NY, Li L, Yoshikawa K, Schwartz LM, Oppenheim RW, Milligan CE . 1998 Increased production of amyloid precursor protein provides a substrate for caspase-3 in dying motoneurons J. Neurosci. 18: 5869–5880
Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW . 1999 Involvement of caspases in proteolytic cleavage of Alzherimer's amyloid-β precursor protein and amyloidogenic A β peptide formation Cell 97: 395–406
LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J . 1999 Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease J. Biol. Chem. 274: 23426–23436
Maruyama K, Terakado K, Usami M, Yoshikawa K . 1990 Formation of amyloid-like fibrils in COS cells overexpressing part of the Alzheimer amyloid protein precursor Nature 347: 566–569
Pellegrini L, Passer BJ, Tabaton M, Ganjei JK, D'Adamio L . 1999 Alternative, non-secretase processing of Alzheimer's β-amyloid precursor protein during apoptosis by caspase-6 and -8 J. Biol. Chem. 274: 21011–21016
Weidemann A, Paliga K, Drrwang U, Reinhard FB, Schuckert O, Evin G, Masters CL . 1999 Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases J. Biol. Chem. 274: 5823–5829
Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH, Bredesen DE . 2000 A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor Nat. Med. 6: 397–404
Sahara S, Aoto M, Eguchi Y, Imamoto N, Yoneda Y, Tsujimoto Y . 1999 Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation Nature 401: 168–173
Ohtsubo T, Kamada S, Mikami T, Murakami H, Tsujimoto Y . 1999 Identification of NRF2, a member of the NF-E2 family of transcription factors, as a substrate for caspase-3(-like) proteases Cell Death Differ. 6: 865–872
Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, Novak M, Cattaneo A . 2000 The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis J. Neurochem. 75: 624–633
Chung CW, Song YH, Kim IK, Yoon WJ, Ruy BR, Jo DG, Woo HN, Kwon YK, Kim HH, Gwag BJ, Mook-Jung IH, Jung YK . 2001 Proapoptotic effects of tau cleavage product generated by caspase-3 Neurobiol. Dis. 8: 162–172
Trommsdorff M, Borg JP, Margolis B, Herz J . 1998 Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein J. Biol. Chem. 273: 33556–33560
Tominaga K, Uetsuki T, Ogura A, Yoshikawa K . 1997 Glutamate responsiveness enhanced in neurones expressing amyloid precursor protein Neuroreport 8: 2067–2072
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clements J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Panniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J . 1995 Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein Nature 373: 523–527
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G . 1996 Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice Science 274: 99–102
Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT . 1997 Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F(PDAPP) transgenic mouse J. Neurosci. 17: 7053–7059
Rohn TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH . 2000 A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis J. Neurochem. 74: 2331–2342
Sudo H, Jiang H, Yasukawa T, Hashimoto Y, Niikura T, Kawasumi M, Matsuda S, Takeuchi Y, Aiso S, Matsuoka M, Murayama Y, Nishimoto I . 2000 Antibody-regulated neurotoxic function of cell-surface β-amyloid precursor protein Mol. Cell. Neurosci. 16: 708–723
Stephenson DT, Rash K, Clemens JA . 1992 Amyloid precursor protein accumulates in regions of neurodegeneration following focal cerebral ischemia in the rat Brain Res. 593: 128–135
Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E, Ihara Y, Kawashima S . 1994 Spatial resolution of the primary β-amyloidogenic process induced in postischemic hippocampus J. Biol. Chem. 269: 15253–15257
Benowitz LI, Rodriguez W, Paskevich P, Mufson EJ, Schenk D, Neve RL . 1989 The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects Exp. Neurol. 106: 237–250
Cole GM, Masliah E, Shelton ER, Chan HW, Terry RD, Saitoh T . 1991 Accumulation of amyloid precursor fragment in Alzheimer plaques Neurobiol. Aging 12: 85–91
Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DD, Cotman CW . 1992 Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease Neuroscience 48: 763–777
Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B . 1987 The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor Nature 325: 733–736
Andrews PW . 1984 Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro Dev. Biol. 103: 285–293
Pleasure SJ, Page C, Lee VM . 1992 Pure, postmitotic, polarized human neurons derived from NTera2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons J. Neurosci. 12: 1802–1815
Kouroku Y, Urase K, Fujita E, Isahara K, Ohsawa Y, Uchiyama Y, Momoi MY, Momoi T . 1998 Detection of activated Caspase-3 by a cleavage site-directed antiserum during naturally occurring DRG neurons apoptosis Biochem. Biophys. Res. Commun. 247: 780–784
Van Nostrand WE, Wagner SL, Suzuki M, Choi BH, Farrow JS, Geddes JW, Cotman CW, Cunningham DD . 1989 Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid β-protein precursor Nature 341: 546–549
Gavrieli Y, Sherman Y, Ben-Sasson SA . 1992 Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation J. Cell Biol. 119: 493–501
Acknowledgements
This work was supported by Health Sciences Research Grants (Research on Brain Science) from the Ministry of Health, Labour and Welfare of Japan (to K Yoshikawa), a grant of Research for the Future from the Japan Society for the Promotion of Science (JSPS) (to K Yoshikawa), and JSPS Research Fellowships for Young Scientists (to I Nishimura). We thank Dr. Izumu Saito for adenovirus vectors and Dr. William Van Nostrand for P2-1 antibody.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by H Ichijo
Rights and permissions
About this article
Cite this article
Nishimura, I., Uetsuki, T., Kuwako, K. et al. Cell death induced by a caspase-cleaved transmembrane fragment of the Alzheimer amyloid precursor protein. Cell Death Differ 9, 199–208 (2002). https://doi.org/10.1038/sj.cdd.4400931
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400931
Keywords
This article is cited by
-
Neuroprotection against neurodegenerative diseases
Molecular Neurobiology (2007)
-
A decade of caspases
Oncogene (2003)